Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…, 7

In forcesince 31 Dec 2020

…

Changed on 31 Dec 2020

In order to prepare its opinion, the Committee for Medicinal Products for Human Use: shall verify that the particulars and documents submitted in accordance with Article 6 comply with the requirements of Directive 2001/83/EC, and shall examine whether the conditions specified in this Regulation for granting a marketing authorisation are satisfied; may request that an Official Medicines Control Laboratory or a laboratory that a Member State has designated for that purpose test the medicinal product for human use, its starting materials and, if need be, its intermediate products or other constituent materials in order to ensure that the control methods employed by the manufacturer and described in the application documents are satisfactory; may request that the applicant supplement the particulars accompanying the application within a specific time period. Where the said Committee avails itself of this option, the time-limit laid down in Article 6(3), first subparagraph, shall be suspended until such time as the supplementary information requested has been provided. Likewise, this time-limit shall be suspended for the time allowed for the applicant to prepare oral or written explanations.…

  1. 31 Dec 2020 – todayin force
  2. 26 Jan 2007 – 31 Dec 2020earlier wording

Versions are held from 26 Jan 2007; the article may be older.